A carregar...
EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery
Glioblastoma is the most aggressive malignant brain tumor among all primary brain and central nervous system tumors. The median survival time for glioblastoma patients given the current standard of care treatment (surgery, radiation, and chemotherapy) is less than 15 months. Thus, there is an urgent...
Na minha lista:
| Publicado no: | Receptors Clin Investig |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5341612/ https://ncbi.nlm.nih.gov/pubmed/28286803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14800/rci.1430 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|